Rxi Pharmaceuticals (RXII) is an RNAi biotechnology company that is developing RNAi drug candidates for unmet medical needs. One of its main drugs is known as RXI-109 being developed to treat patients with scars. There is a huge unmet medical need for scars, because the FDA/EMA have no approved drugs at all for scarring.
One of the hardships in the past for RNAi pharmaceutical companies, was being able to allow naked siRNA molecules to penetrate into the cells efficiently. Many trials failed with RNAi, because the siRNA molecules were never able to reach their target, because of the degrading of the molecule. Within the last few years though, three RNAi biotechs known as Alnylam (ALNY...
Only subscribers can access this article, which is part of the PRO research library covering 3,741 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: